BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36412023)

  • 1. [Ⅱ.BRAF-Mutated Colorectal Cancer-Up-to-Date Evidence and Clinical Practice].
    Okura M; Mitani S
    Gan To Kagaku Ryoho; 2022 Nov; 49(11):1216-1220. PubMed ID: 36412023
    [No Abstract]   [Full Text] [Related]  

  • 2. BRAF V600E mutated metastatic colorectal cancer: current progress and future directions.
    Kam AE; Eng C
    Expert Opin Biol Ther; 2021 Oct; 21(10):1311-1313. PubMed ID: 33761808
    [No Abstract]   [Full Text] [Related]  

  • 3. BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?
    Cohen R; Cervera P; Svrcek M; Pellat A; Dreyer C; de Gramont A; André T
    Curr Treat Options Oncol; 2017 Feb; 18(2):9. PubMed ID: 28214977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors.
    Scartozzi M; Giampieri R; Aprile G; Iacono D; Santini D; dell'Aquila E; Silvestris N; Gnoni A; Bonotto M; Puzzoni M; Demurtas L; Cascinu S
    Expert Rev Mol Diagn; 2015; 15(8):979-87. PubMed ID: 25975986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aspirin use and risk of colorectal cancer according to BRAF mutation status.
    Nishihara R; Lochhead P; Kuchiba A; Jung S; Yamauchi M; Liao X; Imamura Y; Qian ZR; Morikawa T; Wang M; Spiegelman D; Cho E; Giovannucci E; Fuchs CS; Chan AT; Ogino S
    JAMA; 2013 Jun; 309(24):2563-71. PubMed ID: 23800934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New Treatment Strategies for BRAF Mutation-Positive Colorectal Cancer].
    Kawakami H; Ogata S
    Gan To Kagaku Ryoho; 2021 Jun; 48(6):787-795. PubMed ID: 34139726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study.
    Wang X; Wei Q; Gao J; Li J; Li J; Gong J; Li Y; Shen L
    Chin J Cancer; 2017 Oct; 36(1):81. PubMed ID: 29037218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF p.Val600Glu (V600E) somatic mutation is mainly associated with MSS phenotype in metastatic colorectal cancer.
    Qiu J; Compagnone M; Laibe S; Lagarde A; Goncalves A; Turrini O; Xerri L; Monges G; Olschwang S
    Cancer Genomics Proteomics; 2011; 8(1):15-8. PubMed ID: 21289333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC.
    Graf W; Cashin PH; Ghanipour L; Enblad M; Botling J; Terman A; Birgisson H
    Ann Surg Oncol; 2020 Jan; 27(1):293-300. PubMed ID: 31571052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of anthropometric factors with KRAS and BRAF mutation status of primary colorectal cancer in men and women: a cohort study.
    Brändstedt J; Wangefjord S; Nodin B; Eberhard J; Sundström M; Manjer J; Jirström K
    PLoS One; 2014; 9(2):e98964. PubMed ID: 24918610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Don't abandon BRAF-mutated patients with peritoneal metastasis! Re: « Therapeutic implications of B-RAF mutations in colorectal cancer ».
    Noiret B; Piessen G; Eveno C
    J Visc Surg; 2022 Feb; 159(1):85. PubMed ID: 34802948
    [No Abstract]   [Full Text] [Related]  

  • 12. An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer.
    Epperla N; George B
    J Gastrointest Cancer; 2016 Jun; 47(2):206-9. PubMed ID: 26018827
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E-Mutated Metastatic Colorectal Cancer.
    Akhoundova D; Pietge H; Hussung S; Kiessling M; Britschgi C; Zoche M; Rechsteiner M; Weber A; Fritsch RM
    JCO Precis Oncol; 2021 Nov; 5():1082-1087. PubMed ID: 34994629
    [No Abstract]   [Full Text] [Related]  

  • 14. A validated prognostic classifier for
    Loupakis F; Intini R; Cremolini C; Orlandi A; Sartore-Bianchi A; Pietrantonio F; Pella N; Spallanzani A; Dell'Aquila E; Scartozzi M; De Luca E; Rimassa L; Formica V; Leone F; Calvetti L; Aprile G; Antonuzzo L; Urbano F; Prenen H; Negri F; Di Donato S; Buonandi P; Tomasello G; Avallone A; Zustovich F; Moretto R; Antoniotti C; Salvatore L; Calegari MA; Siena S; Morano F; Ongaro E; Cascinu S; Santini D; Ziranu P; Schirripa M; Buggin F; Prete AA; Depetris I; Biason P; Lonardi S; Zagonel V; Fassan M; Di Maio M
    Eur J Cancer; 2019 Sep; 118():121-130. PubMed ID: 31330487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An amino-terminal
    Tung JK; Neishaboori N; Haraldsdottir S; Suarez CJ
    Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32669268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer.
    Takahashi H; Takahashi M; Ohnuma S; Unno M; Yoshino Y; Ouchi K; Takahashi S; Yamada Y; Shimodaira H; Ishioka C
    BMC Cancer; 2017 Nov; 17(1):723. PubMed ID: 29115941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
    Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of immunohistochemistry for the detection of the BRAF V600E mutation in colorectal carcinoma.
    Ioannou M; Papamichali R; Samara M; Paraskeva E; Papacharalambous C; Baxevanidou K; Koukoulis G
    J BUON; 2016; 21(3):618-25. PubMed ID: 27569082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
    Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
    Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases.
    Bachet JB; Moreno-Lopez N; Vigano L; Marchese U; Gelli M; Raoux L; Truant S; Laurent C; Herrero A; Le Roy B; Deguelte Lardiere S; Passot G; Hautefeuille V; De La Fouchardiere C; Artru P; Ameto T; Mabrut JY; Schwarz L; Rousseau B; Lepère C; Coriat R; Brouquet A; Sa Cunha A; Benoist S
    Br J Surg; 2019 Aug; 106(9):1237-1247. PubMed ID: 31183866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.